Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer
- 30 June 1996
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Obstetrics and Gynecology
- Vol. 174 (6), 1688-1694
- https://doi.org/10.1016/s0002-9378(96)70198-9
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Ovarian CancerJama-Journal Of The American Medical Association, 1995
- Salvage Therapy for Recurrent and Refractory Ovarian Cancer with High-Dose Chemotherapy and Autologous Bone Marrow Support: A Gynecologic Oncology Group Pilot StudyGynecologic Oncology, 1994
- Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993.Journal of Clinical Oncology, 1994
- Dose intensityAnnals of Oncology, 1993
- Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.Journal of Clinical Oncology, 1992
- Impact of autologous bone marrow infusion on hematopoietic recovery after high-dose cyclophosphamide, etoposide, and cisplatin.Journal of Clinical Oncology, 1991
- High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancerGynecologic Oncology, 1990
- High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operationGynecologic Oncology, 1989
- Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.Journal of Clinical Oncology, 1987
- High-dose cisplatin in hypertonic saline in refractory ovarian cancer.Journal of Clinical Oncology, 1985